Nuclear Medicine Is Taking Off — And the Hendricks Family Has a Front‑Row Seat

The nuclear medicine industry is exploding in size — it’s expected to grow by more than 300%  by 2034, according to new research from Fortune Business Insights. That’s a massive jump for a field focused on advanced tools that help doctors diagnose and treat serious diseases like cancer and heart conditions.

The Hendricks family has a stake in this fast‑growing space through Northstar Medical Radioisotopes, a Beloit, Wisconsin company in the Hendricks Holding Company portfolio.

The industry is exploding because three big forces are all hitting at once: demand, technology, and better treatment results. More people need these products, and the science is improving quickly — pushing the U.S. nuclear medicine market into a major growth phase.

Nuclear medicine is growing fast because more people are being diagnosed with cancer, heart disease, and neurological conditions — and doctors need tools that can spot these problems earlier and treat them more precisely.

At the same time, the science behind radiopharmaceuticals is advancing quickly, with new therapies and imaging agents proving they can target disease more effectively than older methods. Hospitals and manufacturers are racing to expand production, and recent FDA approvals are giving the field even more momentum.

Put simply: more patients need these treatments, the technology is getting dramatically better, and the results are strong enough that the healthcare system is leaning in.